Program
TQB6426
A development code. Also written as “TQB6426 for Injection”.
Its studies are led by Sino Biopharmaceutical.
Furthest: phase 1, since Jul 22, 20261 company-led study, 1 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Jul 22, 2026 | Jul 22, 2026 | Aug 2027phase 1 · NCT07730190 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2026First study: phase 1 study in Advanced MalignanciesFirst studyNCT07730190 · 145 planned · China
Ahead
- Aug 2027Primary completion: phase 1 study in Advanced MalignanciesNCT07730190
TargetBeta
GPC3 →read by rule
“TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.”study text, by rule · the study
Other programs on GPC3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| codrituzumab | Hoffmann-La Roche | phase 2 | 3 |
| GPC3-targeted Plasmid DNA Vaccine NWRD06rule | Newish Biotech (Wuxi) | phase 2 | 2 |
| Actinium Ac 225 GPC3-targeted Peptide RYZ801 | Bristol-Myers Squibb | phase 2 | 1 |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ZW251rule | Zymeworks | phase 1 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ABBV-324 | AbbVie | phase 1 | 1 |
| Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | Bayer | phase 1 | 1 |
| ACE723rule | acepodia-biotech-inc | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07730190Advanced Malignancies · China | 1 | Recruiting | Aug 2027 | 145 |
How it is read
Names in the registry
- “TQB6426 for Injection”, 1 entry
Codes read as this program: TQB6426.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.